FDA Advisory Committee Votes 12 to 2 That Benefits of ACADIA Pharmaceuticals’ NUPLAZID™ (Pimavanserin) for the Treatment of Psychosis Associated with Parkinson’s Disease Outweigh the Risks
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Acadia Pharma (ACAD) Fades Early Gains
March 30, 2016 11:56 AM EDTAcadia Pharma (NASDAQ: ACAD) is fading early gains after an FDA panel backed the company's Nuplazid.
Worries about a potential Black Box Warning could be to blame.
Shares are up 9.8% after opening up 20%.
... MoreAegis Capital Affirms Acadia Pharma (ACAD) at 'Buy' Following Positive FDA Panel Review; Sees Nuplazid Approval Soon
March 30, 2016 10:44 AM EDTAegis Capital affirms Acadia Pharma (Nasdaq: ACAD) with a Buy rating and $54 price target following a positive FDA panel review of Acadia's Nuplazid on Tuesday.
Analyst Robert LeBoyer sees post-approval studies for Nuplazid, commenting, Following the results of the Phase III trial in 2013, Acadia met with the FDA and was encouraged to file based only on that trial. Its strong results... More
Needham & Company Remains Bullish on Acadia Pharma (ACAD) Following Positive FDA Vote on Nuplazid
March 30, 2016 6:49 AM EDTNeedham & Company reiterated a Buy rating and $49.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD) following a vote by the FDA Psychopharmacologic Drugs Advisory Committee in favor of Nuplazid approval for treatment of Parkinson's Disease Psychosis. Committee members generally viewed Nuplazid as effective, with a few... More
Acadia Pharmaceuticals (ACAD) PT LIfted to $44 at Piper Jaffray Amid Panel Backing for NUPLAZID
March 30, 2016 6:26 AM EDTPiper Jaffray analyst Charles Duncan reiterated an Overweight rating and boosted his price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $44.00 (from $39.00) after an FDA panel voted positively on three questions regarding efficacy, and safety.
"Given the clear numerical results, and opinions voiced during... More
Acadia Pharma (ACAD) Surges 25% as Trading Resumes
March 29, 2016 5:52 PM EDTAcadia Pharma (NASDAQ: ACAD) is trading up 25.6% as trading resume following FDA panel backing for NUPLAZID.
... MoreAcadia Pharma (ACAD) Resumes Trading at 5:45 PM ET
March 29, 2016 5:43 PM EDTAcadia Pharma (NASDAQ: ACAD) Resumes Trading at 5:45 PM ET
... More